Lopinavir/ritonavir: is early administration better in Covid-19?
DOI:
https://doi.org/10.18203/2320-6012.ijrms20203673Keywords:
Covid-19 pneumonia, Lopinavir, QTc interval, RitonavirAbstract
Background: To share the data of coronavirus 2019 (Covid-19) patients started on lopinavir-ritonavir (lopi/r) in relation to time period from the onset of symptoms.
Method: Observational descriptive study of 23 Covid-19 patients admitted in a tertiary care center in India from March 2020 to May 2020. Patients categorized into 2 groups based on the timing of initiation of lopi/r from the onset of symptoms. Group 1 were given the drug early (≤7 days) and group 2 late (>7 days). The clinical events (oxygen requirement days and ICU stay) and outcomes of hospital stay between the two groups were evaluated.
Results: Patients were started on lopi/r for a period of 14 days on admission, out of which 12 patients were in group 1 and 11 patients in group 2. Underlying co-morbidities were present in 15 patients (65.21%). The mean duration from onset of symptoms to lopi/r initiation was 4 days and 11.1 days in Group 1 and 2 respectively. Requirement for oxygen support (2.16 versus 6.54 days), mean duration of hospitalization (8.58 versus 11.54 days) and mean duration of obtaining first Covid-19 negative report from the onset of symptoms (10.5 versus 19.57 days) were all significantly lesser in group 1 (p<0.05). All patients belonging to Group 1 and eight patients of group 2 recovered completely and were discharged whereas 3 patients of group 2 expired. Diarrhea was the most commonly observed adverse effect of lopi/r in our patients.
Conclusion: With no approved weapon to tackle the Covid-19 pandemic, we should keep lopi/r in our armamentarium of drugs and use it at the earliest. More clinical trials are needed in future to ascertain if lopi/r can reduce hospital stay, prompt faster recovery and result in better clinical outcome.
References
COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). Johns Hopkins University. Accessed on 9th May2020.
Spychalski P, Spychalska A, Kobiela J. Estimating case fatality rates of Covid-19. Lancet Infect Dis. 2020;20(7):774-5.
Kupferschmidt K, Cohen J. Race to find Covid-19 treatment accelerated. Sci. 2020;367(6485):1412-3.
Zhang, H, Penninger JM, Li, Y. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intens Care Med. 2020;46(4):586-90.
Peiris JS, Chu CM, Cheng VC. Clinical progression and viral load in a community outbreak of coronavirus- associated SARS pneumonia: a prospective study. Lancet. 2003;361(9371):1767-72.
Korean G, King S, Knowles S, Phillips E. Ribavarin in the treatment of SARS: A new trick for an old drug? CMAJ. 2003;168(10):1289-92.
Alhazzani W, Morten M. Surviving sepsis campaign: Guidelines on the management of critically ill adults with coronavirus disease 2019. Intens Care Med. 2020;46(5):854-87.
Niederman MS, Mandell LA, Anzueto A. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention. Am J Respir Crit Care Med. 2001;163(7):1730-54.
Bhatnagar T, Murhekar MV, Soneja M. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use. Indian J Med Res. 2020;151(2/3):184-9.
Chu CM, Cheng VCC, Hung I, Wong M, Chan K, et al. Role of Lopinavir/Ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252-6.
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787-99.
Xiaoting Y, Yunling L, Xia SC, Sun FQ, Ding JG, Zhou Yet al. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease. Eur Rev Med Pharmacol. 2019;24(6):3390-6.
Ivan H, Kwok-Cheung L, Eugene T. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavarin in the treatment of patients admitted to hospital with Covid-19: an open-label, randomized, phase 2 trial. The Lancet. 2020;395(10238):1695-704.
14. Hsu LY, Lee CC, Green JA. Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts. Emerg Infect Dis. 2003;9(6):713-7.
Wang H, Ding Y, Li X, Yang L, Zhang W, Kang W. Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. N Engl J Med. 2003;349:507-8.
Chan KS, Lai ST, Chu CM. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong J. 2003;9(6)399-406.
Arabi YM, Alothman A, Balkhy HH. Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-ß1b (MIRACLE trial): study protocol for a randomized trial. Trials 2018. 2018;19(1):81.
